Combined recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) and nab-paclitaxel/gemcitabine (AG) as the first-line therapy for patients with advanced pancreatic adenocarcinoma: Preliminary results of an open-label, phase Ib/II clinical study.

被引：0
|
作者：
Cheng, Ke
Li, Zhiping
Cao, Dan
机构：
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Canc, Chengdu, Peoples R China
[2] West China Hosp, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16792
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study
    Xu, Rui-hua
    Wang, Fenghua
    Xu, Nong
    Shen, Lin
    Dai, Guanghai
    Yuan, Xianglin
    Shi, Jianhua
    Yang, Shujun
    Feng, Ji Feng
    Hu, Xi-Chun
    Zhang, Qingyuan
    Chen, Ye
    Lin, Xiaoyan
    Ba, Yi
    Liu, Yunpeng
    Jiang, Yi
    Yongqian, Shu
    Li, Qi
    Li, Wei
    Yao, Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study
    Xu, R.
    Wang, F. H.
    Feng, F. J.
    Li, Q.
    Xu, N.
    Hu, X. C.
    Liao, W. J.
    Jiang, Y.
    Lin, X.
    Zhang, Q. Y.
    Yuan, X. L.
    Huang, H. X.
    Chen, Y.
    Dai, G. H.
    Shi, J. H.
    Shen, L.
    Ren, C.
    Wu, H.
    Feng, H.
    Yao, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.
    Wang, Fenghua
    Wei, Xiao-Li
    Feng, Ji Feng
    Li, Qi
    Xu, Nong
    Hu, Xi-Chun
    Jiang, Yi
    Liao, Wangjun
    Zhang, Qingyuan
    Yuan, Xianglin
    Huang, Haixin
    Chen, Ye
    Dai, Guanghai
    Shi, Jianhua
    Shen, Lin
    Yang, Shujun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study
    Xu, Rui-hua
    Wang, Fenghua
    Shi, Jianhua
    Feng, Ji Feng
    Shen, Lin
    Yang, Shujun
    Hu, Xi-Chun
    Dai, Guanghai
    Xu, Nong
    Jiang, Yi
    Yongqian, Shu
    Zhang, Qingyuan
    Chen, Ye
    Yuan, Xianglin
    Lin, Xiaoyan
    Ba, Yi
    Li, Qi
    Li, Wei
    Huang, Haixin
    Yao, Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wanrui
    Li, Xiaofen
    Chang, Chen
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16244 - E16244
  • [6] Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wan-Rui
    Li, Xiaofen
    Tian, Bole
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Recombinant humanised anti-PD-1 monoclonal antibody (JS']JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study
    Xu, Ruihua
    Wang, Fenghua
    Li, Qi
    Shi, Jianhua
    Shen, Lin
    Zhang, Qingyuan
    Yuan, Xianglin
    Jiang, Yi
    Xu, Nong
    Chen, Ye
    Hu, Xichun
    Lin, Xiaoyan
    Yang, Shujun
    Ren, Chao
    LANCET ONCOLOGY, 2017, 18 : S1 - S1
  • [8] Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS']JS001) in Chinese patients with refractory solid tumors
    Wang, F-H.
    Ren, C.
    Zhang, Y.
    Yao, S.
    Feng, H.
    Wu, H.
    Song, H-F.
    Zhang, R.
    Wei, X-L.
    Xia, X-J.
    Zhao, Q.
    Yun, J-P.
    Zou, B-Y.
    Qiu, M.
    Wang, Z-Q.
    Li, Y-H.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study.
    Sheng, Xinan
    Chen, Haige
    Yao, Xin
    Hu, Yi
    Yao, Xudong
    Liu, Ziling
    Zhou, Fangjian
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS']JS001, an anti-PD-1 monoclonal antibody.
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Tang, Bixia
    Yan, Xieqiao
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345